查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1285898

作用於RAS的藥劑市場（藥物類別：ACE抑製劑、血管緊張素II受體阻斷劑[ARB]、腎素抑製劑、醛固酮拮抗劑及其他） - 2023-2031年全球行業分析、規模、佔有率、成長、趨勢和預測

RAS-acting Agents Market (Drug Class: ACE Inhibitors, Angiotensin II Receptor Blockers [ARBs], Renin Inhibitors, Aldosterone Antagonists, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 209 Pages | 商品交期: 2-10個工作天內

價格

RAS-反應劑市場- 報告範圍

TMR關於全球RAS反應劑市場的報告研究了過去以及當前的成長趨勢和機會，以獲得對2023年至2031年預測期間市場指標的寶貴見解。報告提供了2017-2031年期間全球RAS-反應劑市場的收入，考慮到2023年為基準年，2031年為預測年。報告還提供了2023年至2031年全球RAS-反應劑市場的複合年成長率（CAGR %）。

該報告是在廣泛的研究後編寫的。一級研究涉及大部分的研究工作，其中分析師與關鍵的意見領袖、行業領袖和意見製造者進行了訪談。二級研究包括參考主要參與者的產品資料、年度報告、新聞稿和相關文件，以了解等離子體材料市場。

該報告深入研究了全球等離子體材料市場的競爭格局。已經確定了在全球RAS-acting Agents市場上運作的主要參與者，並從各種屬性方面對其中的每一個參與者進行了分析。公司概況、財務狀況、最近的發展和SWOT是本報告對全球RAS-反應劑市場參與者的屬性描述。

目錄

第一章：前言

  • 市場定義和範圍
  • 市場細分
  • 主要研究目標
  • 研究重點

第二章：假設和研究方法

第三章：執行摘要：全球市場

第四章：市場概述

  • 簡介
    • 細分市場的定義
    • 行業演變/發展
  • 市場概況
  • 市場動態
    • 驅動力
    • 限制因素
    • 機會
  • 2017-2031年全球市場分析與預測

第5章：關鍵洞察力

  • 技術進步
  • 全球主要國家的疾病流行率和發病率
  • 關鍵的行業事件
  • COVID-19的影響分析

第六章：全球市場分析和預測：按藥物類別分類

  • 介紹和定義
  • 主要研究結果/發展
  • 市場價值預測：按藥物類別，2017-2031年
    • ACE抑製劑
    • 血管緊張素II受體阻斷劑（ARBs）
    • 腎素抑製劑
    • 醛固酮拮抗劑
    • 其他（利尿劑）
  • 市場吸引力分析：按藥物類別

第7章：全球市場分析和預測：按適應症分類

  • 介紹和定義
  • 主要研究結果/發展
  • 市場價值預測：按適應症分類，2017-2031年
    • 高血壓
    • 心力衰竭
    • 慢性腎臟病
    • 糖尿病腎病
    • 冠狀動脈疾病
  • 市場吸引力分析：按適應症

第八章：全球市場分析與預測：按配銷通路分類

  • 介紹和定義
  • 主要研究結果/發展
  • 市場價值預測：按配銷通路分類，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場吸引力分析：按配銷通路分類

第九章：全球市場分析與預測：按地區分類

  • 主要發現
  • 市場價值預測：按地區分類，2017-2031年
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第十章：北美市場分析與預測

  • 簡介
    • 主要研究結果
  • 市場價值預測：按藥物類別，2017-2031年
    • ACE抑製劑
    • 血管緊張素II受體阻斷劑（ARBs）
    • 腎素抑製劑
    • 醛固酮拮抗劑
    • 其他（利尿劑）
  • 市場價值預測：按適應症，2017-2031年
    • 高血壓
    • 心力衰竭
    • 慢性腎臟病
    • 糖尿病腎病
    • 冠狀動脈疾病
  • 市場價值預測：按配銷通路，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家分類，2017-2031年
    • 美國
    • 加拿大
  • 市場吸引力分析
    • 按藥物類別
    • 按適應症分類
    • 按銷售管道分類
    • 按國家分類

第11章：歐洲市場分析和預測

  • 簡介
    • 主要發現
  • 市場價值預測：按藥物類別，2017-2031年
    • ACE抑製劑
    • 血管緊張素II受體阻斷劑（ARBs）
    • 腎素抑製劑
    • 醛固酮拮抗劑
    • 其他（利尿劑）
  • 市場價值預測：按適應症，2017-2031年
    • 高血壓
    • 心力衰竭
    • 慢性腎臟病
    • 糖尿病腎病
    • 冠狀動脈疾病
  • 市場價值預測：按配銷通路，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家/次區域分類，2017-2031年
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 市場吸引力分析
    • 按藥物類別
    • 按適應症分類
    • 按配銷通路分類
    • 按國家/次區域分類

第十二章：亞太地區市場分析和預測

  • 簡介
    • 主要發現
  • 市場價值預測：按藥物類別，2017-2031年
    • ACE抑製劑
    • 血管緊張素II受體阻斷劑（ARBs）
    • 腎素抑製劑
    • 醛固酮拮抗劑
    • 其他（利尿劑）
  • 市場價值預測：按適應症，2017-2031年
    • 高血壓
    • 心力衰竭
    • 慢性腎臟病
    • 糖尿病腎病
    • 冠狀動脈疾病
  • 市場價值預測：按配銷通路，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家/次區域分類，2017-2031年
    • 中國
    • 日本
    • 印度
    • 澳大利亞和新西蘭
    • 亞太其他地區
  • 市場吸引力分析
    • 按藥物類別
    • 按適應症分類
    • 按配銷通路
    • 按國家/次區域分類

第13章：拉丁美洲（LATAM）市場分析和預測

  • 簡介
    • 主要發現
  • 市場價值預測：按藥物類別，2017-2031年
    • ACE抑製劑
    • 血管緊張素II受體阻斷劑（ARBs）
    • 腎素抑製劑
    • 醛固酮拮抗劑
    • 其他（利尿劑）
  • 市場價值預測：按適應症，2017-2031年
    • 高血壓
    • 心力衰竭
    • 慢性腎臟病
    • 糖尿病腎病
    • 冠狀動脈疾病
  • 市場價值預測：按配銷通路，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家/次區域分類，2017-2031年
    • 巴西
    • 墨西哥
    • 拉美其他地區
  • 市場吸引力分析
    • 按藥物類別
    • 按適應症分類
    • 按配銷通路分類
    • 按國家/次區域分類

第十四章：中東和非洲市場分析和預測

  • 簡介
    • 主要發現
  • 市場價值預測：按藥物類別，2017-2031年
    • ACE抑製劑
    • 血管緊張素II受體阻斷劑（ARBs）
    • 腎素抑製劑
    • 醛固酮拮抗劑
    • 其他（利尿劑）
  • 市場價值預測：按適應症，2017-2031年
    • 高血壓
    • 心力衰竭
    • 慢性腎臟病
    • 糖尿病腎病
    • 冠狀動脈疾病
  • 市場價值預測：按配銷通路，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家/次區域分類，2017-2031年
    • 海灣合作委員會國家
    • 南非
    • 中東和非洲其他地區
  • 市場吸引力分析
    • 按藥物類別
    • 按適應症分類
    • 按配銷通路分類
    • 按國家/次區域分類

第十五章：競爭格局

  • 市場參與者- 競爭矩陣（按公司層級和規模）。
  • 市場佔有率分析：按公司分類(2022)
  • 公司簡介
    • Novartis AG
    • Pfizer, Inc.
    • AstraZeneca plc
    • Merck & Co., Inc.
    • Sanofi SA
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company, Limited
    • Takeda Pharmaceutical Company Limited
    • Boehringer Ingelheim GmbH
    • Johnson & Johnson
Product Code: TMRGL85539

RAS-acting Agents Market - Scope of Report

TMR's report on the global RAS-acting Agents Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global RAS-acting Agents Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global RAS-acting Agents Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the RAS-acting Agents market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global RAS-acting Agents market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global RAS-acting Agents market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global RAS-acting Agents market.

The report delves into the competitive landscape of the global RAS-acting Agents market. Key players operating in the global RAS-acting Agents Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global RAS-acting Agents Market profiled in this report.

Key Questions Answered in Global RAS-acting Agents Market Report:

  • What is the sales/revenue generated by RAS-acting Agents across all regions during the forecast period?
  • What are the opportunities in the global RAS-acting Agents market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

RAS-acting Agents Market - Research Objectives and Research Approach

The comprehensive report on the global RAS-acting Agents Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global RAS-acting Agents Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global RAS-acting Agents market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global RAS-acting Agents Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global RAS-acting Agents Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
  • 5.3. Key Industry Events
  • 5.4. COVID-19 Impact Analysis

6. Global RAS-acting Agents Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. ACE inhibitors
    • 6.3.2. Angiotensin II Receptor Blockers (ARBs)
    • 6.3.3. Renin Inhibitors
    • 6.3.4. Aldosterone Antagonists
    • 6.3.5. Others (diuretics)
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global RAS-acting Agents Market Analysis and Forecast, by Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Indication, 2017-2031
    • 7.3.1. Hypertension
    • 7.3.2. Heart Failure
    • 7.3.3. Chronic Kidney Disease
    • 7.3.4. Diabetic Nephropathy
    • 7.3.5. Coronary Artery Disease
  • 7.4. Market Attractiveness Analysis, by Indication

8. Global RAS-acting Agents Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global RAS-acting Agents Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America RAS-acting Agents Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. ACE inhibitors
    • 10.2.2. Angiotensin II Receptor Blockers (ARBs)
    • 10.2.3. Renin Inhibitors
    • 10.2.4. Aldosterone Antagonists
    • 10.2.5. Others (diuretics)
  • 10.3. Market Value Forecast, by Indication, 2017-2031
    • 10.3.1. Hypertension
    • 10.3.2. Heart Failure
    • 10.3.3. Chronic Kidney Disease
    • 10.3.4. Diabetic Nephropathy
    • 10.3.5. Coronary Artery Disease
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Indication
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe RAS-acting Agents Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. ACE inhibitors
    • 11.2.2. Angiotensin II Receptor Blockers (ARBs)
    • 11.2.3. Renin Inhibitors
    • 11.2.4. Aldosterone Antagonists
    • 11.2.5. Others (diuretics)
  • 11.3. Market Value Forecast, by Indication, 2017-2031
    • 11.3.1. Hypertension
    • 11.3.2. Heart Failure
    • 11.3.3. Chronic Kidney Disease
    • 11.3.4. Diabetic Nephropathy
    • 11.3.5. Coronary Artery Disease
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Indication
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific RAS-acting Agents Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. ACE inhibitors
    • 12.2.2. Angiotensin II Receptor Blockers (ARBs)
    • 12.2.3. Renin Inhibitors
    • 12.2.4. Aldosterone Antagonists
    • 12.2.5. Others (diuretics)
  • 12.3. Market Value Forecast, by Indication, 2017-2031
    • 12.3.1. Hypertension
    • 12.3.2. Heart Failure
    • 12.3.3. Chronic Kidney Disease
    • 12.3.4. Diabetic Nephropathy
    • 12.3.5. Coronary Artery Disease
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Indication
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America (LATAM) RAS-acting Agents Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. ACE inhibitors
    • 13.2.2. Angiotensin II Receptor Blockers (ARBs)
    • 13.2.3. Renin Inhibitors
    • 13.2.4. Aldosterone Antagonists
    • 13.2.5. Others (diuretics)
  • 13.3. Market Value Forecast, by Indication, 2017-2031
    • 13.3.1. Hypertension
    • 13.3.2. Heart Failure
    • 13.3.3. Chronic Kidney Disease
    • 13.3.4. Diabetic Nephropathy
    • 13.3.5. Coronary Artery Disease
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of LATAM
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Indication
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa RAS-acting Agents Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. ACE inhibitors
    • 14.2.2. Angiotensin II Receptor Blockers (ARBs)
    • 14.2.3. Renin Inhibitors
    • 14.2.4. Aldosterone Antagonists
    • 14.2.5. Others (diuretics)
  • 14.3. Market Value Forecast, by Indication, 2017-2031
    • 14.3.1. Hypertension
    • 14.3.2. Heart Failure
    • 14.3.3. Chronic Kidney Disease
    • 14.3.4. Diabetic Nephropathy
    • 14.3.5. Coronary Artery Disease
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Indication
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Novartis AG
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Drug Class Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Pfizer, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Drug Class Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. AstraZeneca plc
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Drug Class Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Merck & Co., Inc.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Drug Class Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Sanofi S.A.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Drug Class Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Bristol-Myers Squibb Company
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Drug Class Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Daiichi Sankyo Company, Limited
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Drug Class Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Takeda Pharmaceutical Company Limited
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Drug Class Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Boehringer Ingelheim GmbH
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Drug Class Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Johnson & Johnson
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Drug Class Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview

List of Tables

  • Table 01: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 03: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 07: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 08: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 11: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 12: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 15: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 16: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 19: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 20: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 23: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 24: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global RAS-acting Agents Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
  • Figure 02: Global RAS-acting Agents Market Revenue (US$ Mn), by Drug Class, 2022
  • Figure 03: Global RAS-acting Agents Market Value Share, by Drug Class, 2022
  • Figure 04: Global RAS-acting Agents Market Revenue (US$ Mn), by Indication, 2022
  • Figure 05: Global RAS-acting Agents Market Value Share, by Indication, 2022
  • Figure 06: Global RAS-acting Agents Market Revenue (US$ Mn), by Distribution Channel, 2022
  • Figure 07: Global RAS-acting Agents Market Value Share, by Distribution Channel, 2022
  • Figure 08: Global RAS-acting Agents Market Value Share, by Region, 2022
  • Figure 09: Global RAS-acting Agents Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 10: Global RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 11: Global RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 12: Global RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 13: Global RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 14: Global RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 15: Global RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 16: Global RAS-acting Agents Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 17: Global RAS-acting Agents Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 18: North America RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 19: North America RAS-acting Agents Market Attractiveness Analysis, by Country, 2017-2031
  • Figure 20: North America RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 21: North America RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 22: North America RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 23: North America RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 24: North America RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 25: North America RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 26: North America RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 27: Europe RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 28: Europe RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 29: Europe RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 30: Europe RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 31: Europe RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 32: Europe RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 33: Europe RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 34: Europe RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 35: Europe RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 36: Asia Pacific RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 37: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 38: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 39: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 40: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 41: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 42: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 43: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 44: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 45: Latin America RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 46: Latin America RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 47: Latin America RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 48: Latin America RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 49: Latin America RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 50: Latin America RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 51: Latin America RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 52: Latin America RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 53: Latin America RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 54: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 55: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 56: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 57: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 58: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 59: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 60: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 61: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 62: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031